1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI/NIH). The purpose of the NHLBI SBIR Phase IIB Bridge Award is to facilitate and accelerate the capital-intensive steps that are required to transition SBIR/STTR Phase II projects to the commercialization stage by promoting partnerships between SBIR/STTR Phase II awardees and third-par…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) | Research Funding National Institutes of Health NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health challenges.
A major objective of the program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage.
This Notice of Funding Opportunity (NOFO) invites SBIR grant applications from SBCs to support later-stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and which will require eventual Federal regulatory approval/clearance.
The purpose of this NOFO and the resulting Phase IIB awards is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. Projects proposed under this NOFO MUST be relevant to the NHLBI mission (see B. Scientific/Technical Scope).
This NOFO is specifically intended to benefit clinical practice by accelerating the commercialization of novel products that require ultimate approval/clearance by a Federal regulatory agency.
This NOFO will give competitive preference and funding priority to applications deemed likely to result in a clinically-relevant commercial product as indicated by the applicant’s ability to secure independent third-party investor funds that equal or exceed the requested NHLBI funds, and competitive preference and funding priority to applications that show a strong potential for clinically relevant commercial products, as evidenced by the applicant’s ability to secure independent third-party investor funds equal to or exceeding the total requested costs.
Letter of Intent Due Date(s): January 26, 2025; Renewal / Resubmission / Revision Due Date(s): Feb. 26, 2025; RFA-HL-26-014 Expiration Date New Date November 17, 2025 per issuance of NOT-OD-26-006 . Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.
Total funding support (direct costs, indirect costs, fee) for the entire budget period MUST not exceed $3,500,000. For any single year of the project period, it is recommended that the budget not exceed $1,166,667 total funding support.
Applicants that intend to request budgets greater than $1,166,667 total funding support in any year are strongly encouraged to communicate with the Scientific / Research Contact(s) listed under Section VII before applying. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project. Medical - Clinical Science
According to the current listing, eligibility includes: Small businesses. Non-domestic (non-U. S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U. S.) components of U. S. Organizations are not eligible to apply. Confirm the full requirements in the official notice before applying.
The current listing shows award Ceiling: $1,000,000; Estimated Total Program Funding: $5,000,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional) is funded by National Heart, Lung, and Blood Institute (NHLBI/NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Five NHLBI Catalyze Product Definition RFAs — HL-26-016 through HL-26-020 — carry an October 21, 2026 receipt date, budget caps of $300,000 to $400,000 per year, and roughly 8 new awards annually. The science is not the gate. An Accelerator Partner and a 0.25:1 non-federal cost match are, and both take longer to line up than the nine weeks you have left.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article